Overview of stem cell therapy for Crohn's disease

Bibliography

• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117(3):514-21
   PubMed Web of Science ®Google Scholar
• Sanders DSA. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 2005;58:568-72
   PubMed Web of Science ®Google Scholar
• Sémont A, François S, Mouiseddine M, et al. Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol 2006;585:19-30
   PubMed Web of Science ®Google Scholar
• Caplan AI. Mesenchymal stem cells. J Orthotop Res 1991;9(5):641-50
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Gorskaja UF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976;4(5):267-74
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Chailikhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987;20(3):263-72
   PubMedGoogle Scholar
• Friedenstein AJ, Piatetzky S, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966;16:381-90
   PubMedGoogle Scholar
• Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995;18(12):1417-26
   PubMed Web of Science ®Google Scholar
• Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest 1999;103:697-705
   Google Scholar
• Oswald J, Boxberger S, Jørgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-84
   PubMed Web of Science ®Google Scholar
• Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000;61:364-70
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815-22
   PubMed Web of Science ®Google Scholar
• Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105(10): 4120-6
   PubMed Web of Science ®Google Scholar
• Abe K, Nguyen KP, Fine SD, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. PNAS 2007;104(43):17022-7
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007;82(4):887-93
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatability complex. Scand J Immunol 2003;57:11-20
   PubMed Web of Science ®Google Scholar
• Tyndall A, Walker UA, Cope A, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 2007;9:301 [published online 29 January 2007, doi:10.1186/ar2103]
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indolamine 2,3-dioxygenase-mediated tryptophan degredation. Blood 2004;103:4619-21
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26:212-22
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31(10):890-6
   PubMed Web of Science ®Google Scholar
• Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001
   PubMed Web of Science ®Google Scholar
• Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028-38
   PubMed Web of Science ®Google Scholar
• Ringdén O, Uzunel M, Sundberg B, et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:2271-6
   PubMed Web of Science ®Google Scholar
• Duijvestein M, Verwey MH, Fidder HH, et al. Autologous mesenchymal stem cell therapy in patients with refractory Crohn's disease. J Crohns Colitis 2009;3(1):S46-7
   Google Scholar
• Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005;128(3):552-63
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008;57(2):211-7
   PubMed Web of Science ®Google Scholar
• García-Olmo D, García-Arranz M, Herreros D, et al. A Phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48(7):1416-23
   PubMed Web of Science ®Google Scholar
• Onken J, Gallup D, Hanson J et al. Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. ACG 2006 Final Program Book 2006;121
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-9
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: The CHARM trial. Gastroenterology 2007;132(1):52-65
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 2007;146(12):829-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003;75(10):1745-7
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439-41
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a Phase II clinical trial. Dis Colon Rectum 2009;52(1):79-86
   PubMed Web of Science ®Google Scholar
• Onken J, Jaffe T, Custer L. Long-term safety of Prochymal adult mesenchymal stem cells in Crohn's disease. Gastroenterology 2008;134(4):A-661
   Google Scholar
• Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangectasia patient. PLos Med 2009;6(2) [published online 17 February 2009, doi:10.1371/journal.pmed.1000029]
   PubMedGoogle Scholar
• Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262(5):509-25
   PubMed Web of Science ®Google Scholar
• Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81(10):1390-7
   PubMed Web of Science ®Google Scholar
• Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008;112(3):532-41
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and inflximab and azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 2008;103(S1):S436
   Google Scholar